Amneal Pharmaceuticals, Inc. (AMRX) Thursday said that the U.S. Food and Drug Administration (FDA) has approved prednisolone acetate ophthalmic suspension, a generic version of Allergan's Pred Forte.
Prednisolone acetate ophthalmic suspension is indicated for treating steroid-responsive ocular inflammation.
Amneal plans to launch the product in the third quarter of 2025.
According to IQVIA, U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were about $201 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.